DYRK1A: a promising drug target for islet transplant-based diabetes therapies was written by Belgardt, Bengt-Frederik;Lammert, Eckhard. And the article was included in Diabetes in 2016.Formula: C11H13IN4O4 The following contents are mentioned in the article:
A review. This article discussed about dual-specificity tyrosine phosphorylation-regulated kinase as a promising drug target for islet transplant-based diabetes therapies and several other small mols. to induce human β-cell proliferation such as adenosine kinase inhibitor, 5-iodotubercidin which stimulates human β-cell proliferation in vitro, as well as upon transplantation of human islets into mice in vivo and long-term treatment of islets with 5-IT improved glucose-stimulated insulin secretion in type 2 diabetes patients. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Formula: C11H13IN4O4).
(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. Solid acid catalysis, and the advantages often associated with their use, have been proved equally efficient for the synthesis of tetrahydrofurans or furans. Tetrahydrofuran can also be produced, or synthesised, via catalytic hydrogenation of furan. This process involves converting certain sugars into THF by digesting to furfural. An alternative to this method is the catalytic hydrogenation of furan with a nickel catalyst.Formula: C11H13IN4O4
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem